Suraksha Diagnostic posts 21% revenue growth, resumes dividend at ₹0.50
Revenue hit ₹300.68 crore but profit grew just 1.9%. The board has restored a shareholder payout after skipping last year.
— 5 earlier stories on Suraksha Diagnostic Ltd. →What's new
- Standalone revenue grew 20.7% to ₹300.68 crore for FY26.
- Profit after tax rose only 1.9% to ₹34.06 crore despite the top-line jump.
- Board recommended a ₹0.50 per-share dividend, returning to payouts after a one-year gap.
Why this matters
The gap between a 21% revenue rise and a 2% profit rise is the story. Suraksha grew the top line, but costs ate almost all of it. The dividend resumption is a gesture, but the payout ratio is thin. The audit opinion is clean.
What we're watching
- What drove the margin compression in FY26.
- Whether the Fetomat Wellness acquisition adds to the cost base in FY27.
- If the dividend is sustainable given the flat profit trajectory.
The full read
Suraksha Diagnostic's FY26 numbers tell a split story. Standalone revenue climbed 20.7% to ₹300.68 crore, but profit after tax barely budged, rising just 1.9% to ₹34.06 crore. The margin got squeezed. To its credit, the board is resuming a dividend of ₹0.50 per share after paying nothing last year, but the payout is small against the profit base. The audit opinion is clean, and the filing includes routine notes on the Fetomat Wellness acquisition and a subsidiary dispute. This is a standard annual results filing, backward-looking and likely anticipated by the market.
Questions answered
- How much did Suraksha's revenue and profit grow in FY26?
- Standalone revenue from operations grew 20.7% year-on-year to ₹300.68 crore. Profit after tax grew just 1.9% to ₹34.06 crore.
- Why is the dividend notable?
- The board recommended ₹0.50 per equity share after paying no dividend in the prior year. It's a return to shareholder payouts, but the amount is modest given the profit base.
- What is the status of the audit and other filings?
- The results carry an unmodified audit opinion. The filing also includes routine disclosures on the Fetomat Wellness acquisition, a dispute involving a step-down subsidiary, and standard auditor appointments.
Suraksha Diagnostic Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on SURAKSHA →- 21 May 2026 · 6:45 PM IST Suraksha Diagnostic posts 21% revenue growth, resumes dividend at ₹0.50
- 40d ago Suraksha Diagnostic transcript confirms previously issued FY27 guidance
- 45d ago Suraksha Diagnostic cools growth targets to 15% for FY27
- 46d ago Suraksha's revenue grew 22.5%, but profit fell 14% in Q4.
- 46d ago Suraksha Diagnostic revenue lifts 21% as margins tighten